Categories
Anticancer Drugs Bendamustine Medicine Oncology Pharmacology Physiotherapy

Bendamustine

In this article we will discuss about Bendamustine (Dosage Overview)

In this article, we will discuss about Bendamustine (Dosage Overview). So, let’s get started.

Indications

Chronic Lymphocytic Leukemia (CLL)

Bendamustine hydrochloride (BENDEKA™) Injection is indicated for the treatment of patients with chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.

Non-Hodgkin Lymphoma (NHL)

Bendamustine hydrochloride (BENDEKA™) Injection is indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Dosage

Dosing Instructions for CLL

Recommended Dosage
The recommended dose is 100 mg/m administered intravenously over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles.

Dose Delays, Dose Modifications and Reinitiation of Therapy for CLL:

Bendamustine hydrochloride (BENDEKA™) Injection administration should be delayed in the event of Grade 4 hematologic toxicity or clinically significant greater than or equal to Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10⁹/L. platelets greater than or equal to 75 x 10⁹/L]. Bendamustine hydrochloride (BENDEKA™) Injection can be reinitiated at the discretion of the treating physician. In addition, dose reduction may be warranted.

Dose modifications for hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 50 mg/m² on Days 1 and 2 of each cycle: if Grade 3 or greater toxicity recurs, reduce the dose to 25 mg/m² on Days 1 and 2 of each cycle.

Dose modifications for non-hematologic toxicity: for clinically significant Grade 3 or greater toxicity, reduce the dose to 50 mg mon Days 1 and 2 of each cycle. Dose re-escalation in subsequent cycles may be considered at the discretion of the treating physician.

Dosing Instructions for NHL

Recommended Dosage
The recommended dose is 120 mg/m² administered intravenously over 10 minutes on Days 1 and 2 of a 21-day evcle, up to 8 cycles.

Dose Delays, Dose Modifications and Reinitiation of Therapy for NHL:

Bendamustine hydrochloride (BENDEKA™) Injection administration should be delayed in the event of a Grade 4 hematologic toxicity or clinically significant greater than or equal to Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to less than or equal to Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10⁹/L, platelets greater than or equal to 75 x 10⁹/L], Bendamustine hydrochloride (BENDEKA™) Injection can be reinitiated at the discretion of the treating physician. In addition, dose reduction may be warranted.

Dose modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m² on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m² on Days 1 and 2 of each cycle.

Dose modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m² on Days 1 and 2 of each cycle: if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m² on Days 1 and 2 of each cycle.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.